These documents matter because they prove there is no legal barrier to the health minister directing the PBAC in how it applies the cost-effectiveness framework and that, in fact, this exercise of power is critical to achieving real change.
The minister exercised their power, the PBAC welcomed it, and the system changed
January 9, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News -
Guild says pharmacy a solution as AMA flags ambulance ramping crisis
June 26, 2026 - - Latest News -
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News


